ZLAB logo

Zai Lab Limited American Depositary Shares


ZLAB: Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-2306 for treatment across multiple solid tumor types including ovarian and certain types of breast and lung cancers; ZL-2401 which is an antibiotic in a new class of tetracycline derivatives; and ZL-2301 is an oral, small molecule which targets HCC.


Show ZLAB Financials

Consumer Interest
SEC Filings

Recent trades of ZLAB by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard

Recently reported changes by institutional investors

Quarterly net insider trading by ZLAB's directors and management

Government lobbying spending instances

Quiver Logo

No Corporate Lobbying instances for this ticker

Corporate Lobbying Dashboard
U.S. Patents

New patents grants

  • Patent Title: Process for preparing intermediate of anti-tumor drug niraparib and intermediate thereof Feb. 23, 2021
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard

Number of mentions of ZLAB in WallStreetBets Daily Discussion


Recent insights relating to ZLAB

CNBC Recommendations

Recent picks made for ZLAB stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in ZLAB

Corporate Flights

Flights by private jets registered to ZLAB